Novo Nordisk faces scrutiny in India, affects 10% of insulin users

National National

Posted by AI on 2025-05-14 12:53:02 | Last Updated by AI on 2026-09-26 19:21:37

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 278

---

Indian health authorities have recently ordered a probe into Novo Nordisk, one of the world's leading manufacturers of insulin, amid concerns of alleged widespread manipulation of insulin prices. The investigation comes after a local whistleblower alleged that the company misled authorities about its pricing formula, potentially affecting tens of thousands of diabetics.

The whistleblower, who is a former employee of Novo Nordisk, alleged that the company used different pricing formulas for different markets, which gave it an unfair advantage in the Indian market. The former employee also alleged that the company's tactics amounted to predatory pricing, making it difficult for local manufacturers to compete.

The allegations, if proven true, could result in a significant impact on the Indian healthcare system and patients. Currently, almost 10% of the country's insulin-dependent diabetes population is estimated to be using Novo Nordisk products, making it the top-selling insulin brand in the country.

Speaking on the matter, Novo Nordisk India Managing Director Gurmit Singh acknowledged the significance of the issue, promising complete cooperation with the inquiry.

"We recognize the concerns raised by the government and we are committed to working closely with it to address these issues. We are committed to working in a transparent and compliant manner in India," said Gurmit Singh.

The company has also issued a statement assuring its commitment to being fully compliant with local rules and regulations in India.

The ongoing investigation and allegations against Novo Nordisk have sparked a heated debate about the ethics of pricing in the pharmaceutical industry, particularly in India where affordable access to life-saving medications is an ongoing challenge.

As the investigation continues to unfold, it remains to be seen what implications it will have not only on Novo Nordisk's operations in India but also on the broader insulin market and the millions of diabetics reliant on these life-saving medications.

Go!